摘要:
Disclosed is a compound having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.
摘要:
Disclosed is a compound of having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.
摘要:
Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists
摘要:
Disclosed is a compound of having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.
摘要:
Disclosed is a compound of having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.
摘要:
Disclosed is a compound having the formula pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.
摘要:
Disclosed is a compound of having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.
摘要:
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
摘要:
The fungicidal compound 4,5-dimethyl-N-2-propenyl-2-(trimethylsilyl)-3-thiophenecarboxamide (Formula (I)) has shown superior and unexpected control of the growth of the soil-borne fungus Gaeumannomyces graminis (Gg). The present invention provides a novel compound for synthesizing the compound of Formula (I) which uses the compound 4-hydroxy-4,5-dimethyl-2-trimethylsilanyl-dihydrothiophene-3-carboxylic acid allylamide (Formula (II)) as well as novel compounds of synthesizing the allylamide. In addition, Formula (II) itself has unexpectedly been found to provide control of Gg. Therefore, the compounds having Formula (III): or an agronomic salts and compositions thereof are expected to provide such control as well; wherein: Q is —NH, S, or O; W is O, or S; X is —OH, —OAc, —OR, where R is lower alkyl; Y is S, O, or —NH; Z is —Si(R)3, —C(R)3, where R is lower alkyl; R1 is a lower alkyl, allyl, or propargyl; R2 is a lower alkyl or aryl; and R3 and R4 are independently chosen from hydrogen, a lower alkyl and aryl; optionally, R2 and R3 together form a 5- or 6-membered ring.
摘要翻译:杀真菌化合物4,5-二甲基-N-2-丙烯基-2-(三甲基甲硅烷基)-3-噻吩甲酰胺(式(I))显示出对土壤真菌Gaeumannomyces graminis(Gg)生长的优异和意想不到的控制, 。 本发明提供用于合成式(I)的化合物的新型化合物,其使用化合物4-羟基-4,5-二甲基-2-三甲基硅烷基 - 二氢噻吩-3-甲酸烯丙基酰胺(式(II))以及 合成烯丙基酰胺的新型化合物。 此外,公式(II)本身意外地被发现提供了GG的控制。 因此,具有式(III)的化合物或其农艺盐及其组合物预期也提供这种控制; 其中:Q是-NH,S或O; W是O或S; X是-OH,-OAc,-OR,其中R是低级烷基; Y是S,O或-NH; Z是-Si (R)3,-C(R)3,其中R是低级烷基; R 1是低级烷基,烯丙基或炔丙基; R 2是低级烷基或芳基; R 3和R 4独立地选自氢,低级烷基和芳基;任选地,R 2和R 3一起形成5-或6-元环。
摘要:
This disclosure relates to an improved process for the preparation of regadenoson, pharmaceutically acceptable salts thereof, and hydrates thereof, and for the preparation of intermediates useful in the synthesis of regadenoson. The disclosure also relates to a new crystalline form of regadenoson. Processes for the preparation of the crystalline form, compositions containing the crystalline form, and methods of use thereof are also described.